Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Our New Real-World Evidence Published!
Multicenter study on Enfortumab Vedotin (EV) in metastatic urothelial carcinoma (mUC) is now out in European Urology Open Science.
After the landmark EV-301 trial established EV’s efficacy, a critical question remained: How does it perform in the diverse, real-world patient population, especially after a specific sequence of platinum-based chemotherapy (PBC) followed by pembrolizumab (PEM)?
The ARON-2EV global project set out to answer this. We analyzed data from 401 patients across 24 countries who received this exact treatment sequence.
Here are the key findings:
Consistent Efficacy: In this real-world setting, EV demonstrated robust activity.
Median Overall Survival (OS): 12.3 months
Overall Response Rate (ORR): 45%
These results strongly align with the pivotal EV-301 trial, confirming EV’s vital role in the post-platinum and post-immunotherapy space.
A Predictive Signal? We discovered a significant association between a patient’s response to prior pembrolizumab and their subsequent outcomes with EV.
Patients who achieved a Complete or Partial Response (CR/PR) to PEM had significantly better OS and Time on Treatment (ToT) with EV.
Crucially, EV was still effective even in patients refractory to PEM, with an ORR of 35%. This underscores its value across different clinical scenarios.
Why it matters:
This large, international analysis provides robust confirmation of EV’s effectiveness in everyday practice. It also offers clinicians valuable insights for patient counseling and suggests that prior immunotherapy outcomes could help inform expectations for subsequent ADC therapy.
This work would not have been possible without the incredible collaboration of all the co-authors and participating centers in the ARON-2EV project led by Matteo Santoni.”
Title: Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Authors: Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, Enrique Grande, Patrizia Giannatempo, Tarek Taha, Zin W. Myint, Thomas Büttner, Alfonso Gómez de Liaño, Ravindran Kanesvaran, Gaetano Facchini, Akihiro Yano, Luigi Formisano, Alexandr Poprach, Vincenza Conteduca, Alina Pirshtuk, Hana Studentova, Jindrich Kopecky, Enrico Sammarco, Augusto Mota, Lorena Incorvaia, Cecilia Nasso, Michele Maffezzoli, Aruni Ghose, Andrey Soares, Sebastiano Buti, Fernando Sabino Marques Monteiro, Francesco Massari, Shilpa Gupta, Joaquim Bellmunt, Giuseppe Luigi Banna, Matteo Santoni
More posts featuring Giuseppe Banna on OncoDaily.
